# Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel)

> **NCT06656624** · PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 190 (estimated)

## Conditions studied

- Advanced Breast Cancer

## Interventions

- **DRUG:** Ribociclib combined with AI±OFS
- **DRUG:** physician's choice of chemotherapy sequential Ribociclib combined with AI±OFS

## Key facts

- **NCT ID:** NCT06656624
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-13
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 190 (ESTIMATED)
- **Last updated:** 2024-10-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06656624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06656624, "Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06656624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*